-

Medincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline

In collaboration with AbbVie, initiation of preclinical and supportive CMC* work to advance a first Long-Acting Injectable candidate into clinical development

MONTPELLIER, France--(BUSINESS WIRE)--Collaboration with AbbVie

  • Initiation of preclinical and supportive CMC* work to advance LAI candidate into clinical development

Collaboration with Teva

  • UZEDY® (risperidone LAI)
  • Reaffirming revenue guidance for 2024 by Teva: c.$80 million
  • Exploring an additional indication for the treatment of Bipolar I Disorder in adults
  • Olanzapine LAI
  • No PDSS** observed after completion of c.95% of the targeted injections for submission (July 31, 2024)
  • Full phase 3 safety results on track for H2 2024

Other in-house and partnered assets

  • mdc-CWM (post operative pain): ongoing review of completed phase 3 study by Medincell partner Arthritis Innovation Corporation (AIC) with plans to meet with FDA in Q4 2024 to discuss additional studies required for approval
  • mdc-WWM (contraception): CMC activities ongoing for initiation of clinical phase 1 activities in 2025
  • mdc-STM (malaria): CMC activities ongoing for initiation of clinical phase 1 activities in 2025
  • Over 10 in-house or partnered active programs currently at formulation stage

ACCESS HERE FOR THE FULL PRESS RELEASE

*CMC (Chemistry, Manufacturing, and Controls) in the pharmaceutical industry refers to the essential documentation and processes related to the chemical composition, manufacturing methods, and quality control measures of a drug, ensuring it meets regulatory standards for safety, efficacy, and quality.

**PDSS = Post injection Delirium/Sedation Syndrome

Contacts

David Heuzé - Head of Corporate and Financial Communications, and ESG
david.heuze@medincell.com / +33 (0)6 83 25 21 86

Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023

Investors Relations France
Louis-Victor Delouvrier/Alban Dufumier
medincell@newcap.eu / +33 (0)1 44 71 94 94

Media Relations
Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94

Industry:

Medincell

BOURSE:MEDCL
Release Versions
English

Contacts

David Heuzé - Head of Corporate and Financial Communications, and ESG
david.heuze@medincell.com / +33 (0)6 83 25 21 86

Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023

Investors Relations France
Louis-Victor Delouvrier/Alban Dufumier
medincell@newcap.eu / +33 (0)1 44 71 94 94

Media Relations
Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94

More News From Medincell

Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached $63 million in Q1 2026, representing a 62% increase from $39 million in Q1 2025 and a 15% increase from $55 million in Q4 2025. Medincell receives mid‑ to high‑single-digit royalties on UZEDY net sales and is eligible for up to $105M in commercial milestone payments, subject to the achievement of annual sa...

Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the initiation of coverage by Degroof Petercam, a leading European investment bank with strong healthcare expertise. Christophe Douat, CEO of Medincell, said: “Broader analyst coverage in Europe and the United States reflects the growing transatlantic interest in Medincell and...

Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the initiation of coverage by Leerink Partners, a healthcare-focused investment bank based in the United States. Christophe Douat, CEO of Medincell, said: “The initiation of coverage by Leerink Partners reflects the growing recognition of Medincell’s within the U.S. biopharmace...
Back to Newsroom